About this Research Topic
Diabetes mellitus (DM) and osteoporosis (OP) are metabolic diseases with significant associated morbidity. Studies found that the prevalence of OP in diabetic patients was 27.67%, which is 4-5 times higher than that in non-diabetic patients. DM is known to be a major cause of secondary osteoporosis, which is related to the loss of bone quality due to the decrease of bone quality and loss of bone mass, and diabetic osteoporosis (DOP) has become a common clinical problem. Studies have shown that both poor control of blood glucose and loss of calcium and phosphorus are risk factors for increased fracture in diabetic patients. Meanwhile, diabetic vascular complications and thiazolidinediones have adverse effects on bone metabolism.
Current Bone Density and Fracture Risk Assessment Tool underestimates the fracture risk in diabetic patients. Therefore, some studies suggest that the therapeutic T-score for T2DM should be set at -2.0. In addition, bone ultrasound, HR-pQCT, MRI, and trabecular bone score may be better tools to assess fracture risk in diabetic patients. Good glycemic control, proper diet, vitamin D and calcium supplementation, exercise, lifestyle interventions, and fall prevention help prevent DOP. In terms of treatment, some drugs including metformin, glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, alendronate, and teriparatide may be more beneficial in DOP. However, more research is needed to explore the prevention and treatment of DOP.
This Research Topic pays close attention to the prevention of diabetic osteoporosis. We welcome submissions analyzing the risk factors, pathogenesis, and screening tools for osteoporosis in diabetic patients. We are also interested in the treatment of secondary osteoporosis in both types of diabetes. Clinical evidence and investigation of underlying mechanisms are encouraged.
Potential sub-topics include but are not limited to:
● Effective preventive measures and early screening methods for patients with diabetic osteoporosis.
● The risk factors, and pathogenesis for osteoporosis in diabetic patients.
● The new treatment strategy or promising therapeutic drug for patients with diabetic osteoporosis.
Current Bone Density and Fracture Risk Assessment Tool underestimates the fracture risk in diabetic patients. Therefore, some studies suggest that the therapeutic T-score for T2DM should be set at -2.0. In addition, bone ultrasound, HR-pQCT, MRI, and trabecular bone score may be better tools to assess fracture risk in diabetic patients. Good glycemic control, proper diet, vitamin D and calcium supplementation, exercise, lifestyle interventions, and fall prevention help prevent DOP. In terms of treatment, some drugs including metformin, glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, alendronate, and teriparatide may be more beneficial in DOP. However, more research is needed to explore the prevention and treatment of DOP.
This Research Topic pays close attention to the prevention of diabetic osteoporosis. We welcome submissions analyzing the risk factors, pathogenesis, and screening tools for osteoporosis in diabetic patients. We are also interested in the treatment of secondary osteoporosis in both types of diabetes. Clinical evidence and investigation of underlying mechanisms are encouraged.
Potential sub-topics include but are not limited to:
● Effective preventive measures and early screening methods for patients with diabetic osteoporosis.
● The risk factors, and pathogenesis for osteoporosis in diabetic patients.
● The new treatment strategy or promising therapeutic drug for patients with diabetic osteoporosis.
Keywords: Diabetes Mellitus, Osteoporosis, Diabetic osteoporosis, Prevention, Therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
